Literature DB >> 32668319

Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study.

Nicolas Hanset1, Selda Aydin2, Nathalie Demoulin1, Jean-Pierre Cosyns2, Diego Castanares-Zapatero3, Ralph Crott4, Jean-François Cambier5, Jean-Michel Pochet6, Gaëlle Gillerot7, Francois Reginster8, Frédéric Houssiau9, Hanna Debiec10, Pierre Ronco11, Michel Jadoul1, Johann Morelle12.   

Abstract

RATIONALE &
OBJECTIVE: Membranous nephropathy (MN) is characterized by the deposition of immune complexes along glomerular basement membranes. M-Type phospholipase A2 receptor (PLA2R), thrombospondin type 1 domain-containing 7A (THSD7A), exostosin 1 and 2 (EXT1/2), and neural epidermal growth factor-like 1 protein (NELL-1) have been identified as established or potential podocyte antigens in MN. We investigated the association of podocyte antigen staining with MN clinical phenotype and outcomes. STUDY
DESIGN: Multicenter retrospective cohort study. SETTING & PARTICIPANTS: 177 consecutive patients with MN unrelated to lupus erythematosus, identified after screening of 3,875 native kidney biopsies performed in the Belgian UCLouvain Kidney Disease Network from 2000 through 2018. PREDICTOR: Positive immunostaining for podocyte antigens on archived kidney biopsy samples. OUTCOMES: Association with different phenotypes (baseline characteristics of patients and pathologic findings on kidney biopsy), time to cancer and to kidney failure. ANALYTICAL APPROACH: Kaplan-Meier estimates and Cox regression analyses to assess time to cancer and kidney failure.
RESULTS: 177 patients were followed up for a median of 4.0 (IQR, 1.3-8.0) years. Diagnosis of PLA2R-positive (PLA2R+), THSD7A+, and double-negative (PLA2R-/THSD7A-) MN was made in 117 (66.1%), 6 (3.4%), and 54 (30.5%) patients, respectively. Progression to kidney failure was similar in all groups. Although the number of patients with THSD7A+MN was small, they showed a higher incidence (50%) and increased risk for developing cancer during follow-up (adjusted HR, 5.0 [95% CI, 1.4-17.9]; P=0.01). 8% and 5% of patients with double-negative MN stained positively for EXT1/2 and NELL-1, respectively. Most patients with EXT1/2+MN were women, had features of systemic autoimmunity, and showed glomerular C1q deposits. LIMITATIONS: Retrospective design; small number of patients in the THSD7A group; lack of evaluation of immunoglobulin G subclasses deposition.
CONCLUSIONS: Our real-world data describe the relative prevalence of subgroups of MN and support the hypothesis that a novel classification of MN based on podocyte antigen staining may be clinically relevant.
Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Membranous nephropathy (MN); cancer; glomerular disease; immunostaining; kidney biopsy; malignancy; nephrotic syndrome; outcome; phospholipase A(2) receptor (PLA(2)R); podocyte antigen; thrombospondin type 1 domain-containing 7A (THSD7A)

Mesh:

Substances:

Year:  2020        PMID: 32668319     DOI: 10.1053/j.ajkd.2020.04.013

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  NELL-1 in Genome-Wide Association Studies across Human Diseases.

Authors:  Xu Cheng; Jiayu Shi; Zhonglin Jia; Pin Ha; Chia Soo; Kang Ting; Aaron W James; Bing Shi; Xinli Zhang
Journal:  Am J Pathol       Date:  2021-12-07       Impact factor: 5.770

Review 2.  Membranous nephropathy: new pathogenic mechanisms and their clinical implications.

Authors:  Elion Hoxha; Linda Reinhard; Rolf A K Stahl
Journal:  Nat Rev Nephrol       Date:  2022-04-28       Impact factor: 42.439

3.  Protocadherin 7-Associated Membranous Nephropathy.

Authors:  Sanjeev Sethi; Benjamin Madden; Hanna Debiec; Johann Morelle; M Cristine Charlesworth; LouAnn Gross; Vivian Negron; David Buob; Sidharth Chaudhry; Michel Jadoul; Fernando C Fervenza; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2021-04-08       Impact factor: 10.121

Review 4.  Membranous nephropathy: current understanding of various causes in light of new target antigens.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 3.416

5.  Prevalence of neural epidermal growth factor-like 1- and exostosin 1/exostosin 2-associated membranous nephropathy: a single-center retrospective study in Japan.

Authors:  Takamasa Iwakura; Chiemi Ema; Shinsuke Isobe; Tomoyuki Fujikura; Naro Ohashi; Akihiko Kato; Hideo Yasuda
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

Review 6.  New antigens involved in membranous nephropathy beyond phospholipase A2 receptor.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Nephrol       Date:  2022-07-25

7.  The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes.

Authors:  Michèle Saïdi; Isabelle Brochériou; Emmanuel Estève; Sophie Tuffet; Zahir Amoura; Makoto Miyara; Xavier Belenfant; Tim Ulinski; Philippe Rouvier; Hanna Debiec; Pierre Ronco; David Buob
Journal:  Kidney Int Rep       Date:  2021-05-05

Review 8.  A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.

Authors:  Pingna Zhang; Weijun Huang; Qiyan Zheng; Jingyi Tang; Zhaocheng Dong; Yuhua Jiang; Yuning Liu; Weijing Liu
Journal:  J Immunol Res       Date:  2021-07-14       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.